Quantum BioPharma Advances Dual Strategy for Neurological Health with Lucid-MS and unbuzzd

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both a novel multiple sclerosis therapy and a dietary supplement for alcohol metabolism. The company is developing Lucid-MS, an investigational therapy designed to target PAD2, an enzyme associated with myelin degradation. Unlike conventional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, offering a disease-modifying approach that could change the landscape of MS care.

The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. This submission marks a critical step toward clinical validation. To support the development, Quantum BioPharma is collaborating with Massachusetts General Hospital on imaging techniques to monitor myelin repair. This partnership could provide objective biomarkers to assess the therapy's efficacy, a significant advantage in clinical trials.

In parallel, Quantum BioPharma is commercializing unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial, suggesting that unbuzzd may offer a practical solution for alcohol-related health issues. The supplement is being marketed through Unbuzzd Wellness Inc. (UWI), a spin-off led by industry veterans, with Quantum BioPharma retaining a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of rights to develop pharmaceutical-grade versions of unbuzzd for medical use.

The dual approach addresses two major neurological challenges: myelin degeneration in MS and the neurotoxic effects of alcohol. By targeting the underlying mechanisms, Quantum BioPharma aims to provide therapies that go beyond symptom management. The company's focus on PAD2 inhibition is particularly noteworthy, as it could lead to neuroprotective and regenerative effects, potentially slowing or reversing disability progression in MS patients.

The Phase 2 trial for Lucid-MS will be pivotal in determining its safety and efficacy in humans. The collaboration with Massachusetts General Hospital is expected to enhance the trial's credibility and data quality. For unbuzzd, the company's strategy to spin out the OTC version while retaining pharmaceutical rights could create multiple revenue streams. The royalty structure ensures long-term financial benefits for Quantum BioPharma as unbuzzd gains market traction.

These developments are significant for the biopharmaceutical industry and for patients. If Lucid-MS succeeds, it could represent a paradigm shift in MS treatment, moving from immunosuppression to myelin repair. Similarly, unbuzzd addresses a widespread public health issue, offering a potential harm-reduction tool. Investors and stakeholders will be watching closely as Quantum BioPharma advances these programs, with the IND submission and clinical trial results being key milestones.

For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM. To view the full article on this development, see https://ibn.fm/Rl89U.